Review Article
The Prognostic Value of Autophagy-Related Markers Bclin-1 and LC-3 in Colorectal Cancers: A Systematic Review and Meta-analysis
Table 1
Features of trials included.
| | Year | Lead author | Country | Median age | TNM stage (I/II/III/IV) | Tumor site (rectum/colon) | Grade (I/II/III) | Method | Sample size (M/W) | Treatment | Survival analysis | Marker | Follow-up period | NOS |
| | 2009 | Li et al. [29] | China | 60 | IIIb | Left hemicolon (70)/right hemicolon (45) | 6/86/23 | IHC | 115 (69/46) | Chemotherapy after operation | OS | Beclin-1 | ≥5 year | 7 |
| | 2013 | Park et al. [30] | USA | 63.5 (26–81) | II (32)/III (146) | Unclear | I/II (119)/III/IV (59) | IHC | 178 (99/79) | Chemotherapy | OS | Beclin-1, LC-3 | Unclear | 5 |
| | 2014 | Choi et al. [22] | Korea | 64 (30–83) | 38/67/101/57 | 111/152 | I/II (222)/III (41) | IHC | 263 (141/122) | Surgery + concurrent chemoradiation therapy/chemotherapy | OS | Beclin-1, LC-3 | 71.4 (0.5–197.4) months | 7 |
| | 2014 | Zhang et al. [34] | China | 65 | I/I (243)/III/IV (234) | Colon | 260/269/35 | IHC | 589 (343/246) | Surgery | OS | Beclin-1 | 13–84 months | 7 |
| | 2015 | Shu-hua et al. [32] | China | 60 | I/II (204)/III/IV (38) | 115/164 | 80/139/60 | IHC | 279 (146/133) | Chemotherapy, operation | OS | Beclin-1, LC-3 | 10–89 months | 7 |
| | 2015 | Shu-hua et al. [24] | China | 60 | Unclear | 96/146 | 67/127/48 | IHC | 242 (127/115) | Chemotherapy, operation | OS | Beclin-1, LC-3 | ≥5 year | 7 |
| | 2015 | Yang et al. [33] | China | 60 | 52/152/121/38 | 173/190 | 31/289/43 | IHC | 363 (199/164) | Surgery | OS, DFS | Beclin-1 | Unclear | 7 |
| | 2016 | Shim et al. [31] | Korea | 62 | II/III | Colon | 18/76/7 | IHC | 101(69/32) | Neoadjuvant chemoradiotherapy and laparoscopic TME | OS, RFS | Beclin-1, LC-3 | ≥5 year | 5 |
| | 2016 | Schmitz et al. [25] | Germany | Unclear | I/II/IV/IV | 80/47 | 28/69/19 | IHC | 127 (66/61) | Surgery | OS | beclin1, LC-3, p65 | 60 months | 7 |
|
|
